Sign in
Taking peoplePhase 3

Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population

Key facts

Who runs it
Salvat
Where
Spain1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
60 people, planned
Started
4 Jan 2023
Expected to end
31 Dec 2032
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Clobetasol Propionate
  • Prednisolone acetate ophthalmic suspension, 1%
Record updated
17 November 2026

Who can take part

Age
0 months to 3 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Male or female, aged 0 to 3 years old (have not had their 4th birthday) on the day of consent
  • Patients who are candidate for routine, uncomplicated cataract surgery in one eye with or without intraocular lens
  • Patients whose caregiver(s) is/are able and willing to comply with all treatment and follow-up procedures
  • Signed informed consent from (ICF) parents or patient's legally authorized representative(s)
  • Patients who have undergone routine, uncomplicated cataract surgery in one eye with or without intraocular lens
  • Patients with clinical evidence of postoperative inflammation (anterior chamber inflammation grade > 0)

Who cannot take part

  • Use of any topical medication in the study eye within 2 days prior to surgery, except for those required for ocular examination or preoperative preparation
  • Systemic administration of any steroidal anti inflammatory drugs in the previous 2 weeks prior to the surgery
  • Systemic administration of any non-steroidal anti inflammatory drugs in the previous 48 hours prior to the surgery
  • Patient or patient's breastfeeding mother who is expected to use corticosteroids (except corticosteroid inhalers and dermatological corticosteroids, as long as they are not used on the eyelids or surrounding area, and oral prednisolone steaglate drops as part of the standard treatment after cataract surgery) or immunosuppressants during the 30 days following cataract surgery
  • Patients with glaucoma, ocular hypertension, or those receiving IOP lowering therapy in either eye or systemically
  • Patients who have had ocular surgery in the study eye within 90 days prior to surgery
  • Any concurrent process which, in the opinion of the investigator, could impair patients' safety or limit adherence to the study protocol
  • Participation in any study of an investigational topical or systemic new drug or device within 30 days prior to screening, or at any time during the study
  • Prior participation in the study described in this protocol unless the patient wasn't randomized
  • Presence of any active or suspected viral, bacterial, or fungal disease in the study eye
  • History of steroid-induced increase in IOP in either eye
  • Known or suspected allergy or hypersensitivity to similar drugs, such as other corticosteroids, or their components
  • History of post-operative unresolved inflammation in the contralateral eye
  • Presence or history of chronic generalized systemic disease that the Investigator believes may either increase the risk to the subject or confound the results of the study (e.g., Diabetes mellitus, human immunodeficiency virus [HIV], acquired immunodeficiency syndrome [AIDS])
  • Active uveitis in the study eye
  • Ocular neoplasia in the study eye
  • Post-traumatic cataract in the study eye
  • Suspected permanent low vision or blindness in the fellow non-study eye. The study eye must not be the patient's only good eye
  • Any current corneal abrasion or ulceration

This trial is currently available in Spain.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Multicenter, randomized, evaluator-blinded clinical trial compared to Prednisolone acetate, 1% in the treatment of inflammation and pain after cataract surgery in pediatric population. This study will assess the safety of Clobetasol propionate ophthalmic nanoemulsion, 0.05% to that of Prednisolone acetate, 1% when administering one drop four times a day (QID) for 14 days followed by a tapering period of 14 days after cataract surgery.

The 2 groups in the trial

  • Clobetasol propionateTreatment being tested

    One drop of Clobetasol propionate ophthalmic nanoemulsion, 0.05% will be administered of the study eye QID beginning the day after surgery (Day 1) for 14 days followed by a tapering period of 14 days.

  • Prednisolone acetateExisting treatment, for comparison

    One drop of Prednisolone ophthalmic suspension, 1% will be administered of the study eye QID beginning the day after surgery (Day 1) for 14 days followed by a tapering period of 14 days.

    Treatment: Prednisolone acetate ophthalmic suspension, 1%

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 3, Multicenter, Randomized, Evaluator-blinded Clinical Trial to Assess the Safety and Efficacy of Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% Compared to Prednisolone Acetate, 1% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population 0 to 3 Years of Age (CLOSE-3)
Record updated
17 November 2026